MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial

Vera Novak(Beth Israel Deaconess Medical Center), Long Ngo(Beth Israel Deaconess Medical Center), Laura Aponte Becerra(Beth Israel Deaconess Medical Center), Péter Novák(Brigham and Women's Hospital), Faizan Khan(University of Ottawa), Catherine B. Fortier(Boston University), Regina E. McGlinchey, Weiying Dai(Binghamton University), Stephanie S. Buss(Beth Israel Deaconess Medical Center), Vasileios Lioutas(Beth Israel Deaconess Medical Center), Christos S. Mantzoros(Harvard University)
Journal of Neurology
April 28, 2022
10.1007/s00415-022-11119-6
Cited by 53

Related Papers

Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis
|BMJ|2019|312
The Boston Assessment of Traumatic Brain Injury–Lifetime (BAT-L) Semistructured Interview
|Journal of Head Trauma Rehabilitation|2013|186
Opioid utilization and opioid‐related adverse events in nonsurgical patients in US hospitals
|Journal of Hospital Medicine|2013|171
Deployment‐Related Psychiatric and Behavioral Conditions and Their Association with Functional Disability in OEF/OIF/OND Veterans
|Journal of Traumatic Stress|2015|158
Plasma proteins and onset of type 2 diabetes and diabetic complications: Proteome-wide Mendelian randomization and colocalization analyses
|Cell Reports Medicine|2023|141